Ask AI
H.R. 2115

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements.

The bill also provides statutory authority for certain provisions of the CMS rule titled "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," published on May 23, 2019. The rule requires, in part, Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that is capable of integrating with at least one prescriber's electronic prescribing system or electronic health record. The tool must provide prescribers with patient-specific, real-time formulary and benefit information, including information regarding cost-sharing, formulary alternatives, and utilization management requirements. The rule takes effect January 1, 2021.

Received in the Senate and Read twice and referred to the Committee on Finance.

Rep. Spanberger, Abigail Davis [D-VA-7](D-VA)Sponsor
5 cosponsors3 D2 R
5cosponsors3committees17actions6related bills6subjects
  1. IntroReferral

    Received in the Senate and Read twice and referred to the Committee on Finance.

    Finance Committee
  2. FloorH38800

    The title of the measure was amended. Agreed to without objection.

  3. FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  4. FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)

  5. Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586).(text: CR H8516)

  6. FloorH30000

    Considered as unfinished business. (consideration: CR H8520-8521)

  7. FloorH37220

    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

  8. FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.

  9. FloorH30000

    Considered under suspension of the rules. (consideration: CR H8516-8519)

  10. FloorH30300

    Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.

  11. Committee

    Subcommittee Hearings Held.

    Health Subcommittee
  12. Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  13. Committee

    Referred to the Subcommittee on Health.

    Ways and Means CommitteeHealth Subcommittee
  14. IntroReferralH11100

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Ways and Means Committee
  15. IntroReferralH11100

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Energy and Commerce Committee
  16. IntroReferralIntro-H

    Introduced in House

  17. IntroReferral1000

    Introduced in House

Oct 28, 201953

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements.

The bill also provides statutory authority for certain provisions of the CMS rule titled "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," published on May 23, 2019. The rule requires, in part, Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that is capable of integrating with at least one prescriber's electronic prescribing system or electronic health record. The tool must provide prescribers with patient-specific, real-time formulary and benefit information, including information regarding cost-sharing, formulary alternatives, and utilization management requirements. The rule takes effect January 1, 2021.

Apr 8, 2019

Public Disclosure of Drug Discounts Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements.

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act — Informed